Cancer Treatment News and Research

RSS

Researchers develop new technology to manage prostate cancer treatment

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

13 May 2010

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 third quarter, ended March 31, 2010.

12 May 2010

Genetic tests represent future of cancer care for women

Important progress is being made in women's health through the use of genetic tests, particularly those that help women detect and treat cancer.

12 May 2010

New computer-based tool developed to benefit cancer patients

Cancer patients and doctors are finally getting on the same page about cancer survivorship, thanks to a free new tool that can benefit anyone who has been diagnosed with cancer.

12 May 2010

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti today announced the launch of the TARGET-PDT project designed to increase the effectiveness of photodynamic therapy for treating cancer by developing a novel nano carrier-based approach.

12 May 2010

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

When one of the country's foremost physicians—people like Dr. Andrew Weil—need someone to care for their friends and family dealing with cancer, the man they turn to is Keith Block, M.D. "I believe in Keith's program and would head to the Block Center if I were facing a diagnosis of cancer. It is where I have and will continue to send my friends and family," said Dr. Weil.

11 May 2010

Cancer costs double in 20 years but are still in line with overall health spending, study finds

USA Today: "The cost of treating cancer has doubled over the past 20 years, but those costs are in line with overall trends in health spending. And while more people are getting cancer as the U.S. population ages, treatment has shifted away from hospitals to outpatient settings, finds a study in Monday's edition of the journal Cancer.

11 May 2010

Personalized treatments for thyroid disorders to be presented at ATA meeting

Internationally recognized thyroid disease experts will meet to discuss "Thyroid Disorders in the Era of Personalized Medicine" May 13 - 16 in Minneapolis, Minnesota at the American Thyroid Association's (ATA) (www.thyroid.org) Spring Meeting to be held at the Minneapolis Hyatt Regency Hotel.

11 May 2010

Costs and quality of cancer care in the U.S.

A new analysis finds that the costs of treating cancer have nearly doubled over the past two decades and that the shares of these costs that are paid for by private health insurance and Medicaid have increased.

10 May 2010

Curis reports net income of $4.8M for first-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2010.

6 May 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

New research by scientists at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas M. D. Anderson Cancer Center could make it easier for patients to use a family of promising experimental cancer therapeutics known as small interfering RNA (siRNA).

6 May 2010

FDA approves Provenge for treating men with advanced prostate cancer

The US Food and Drug Administration has approved a new 'cancer vaccine' for treating men with advanced prostate cancer.

6 May 2010

Decisive impact of informatics on nanomedicine

According to what researchers from Facultad de Informática and other institutions have advanced in an article just published in the prestigious medical journal Pediatric Research (Vol.6, No. 5, 2010), nanoparticles are poised to play a key role in medical research in the coming decades, when nanomedicine will become part of medical practice.

5 May 2010

Canadian Cancer Society awards London scientists new funds for innovative research

Three London scientists are receiving new funding from the Canadian Cancer Society for their work in innovative cancer research.

5 May 2010

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Particular parvoviruses normally infect rodents, but they are also infectious for human cells. However, they do not cause any disease symptoms in humans. Most importantly, these viruses have an astonishing property: They kill infected tumors cells without causing any damage to healthy tissue.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Theragenics reports highest quarterly consolidated revenue of $20.3 million

Theragenics Corporation®, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2010.

4 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

Approval of personalized therapy for lung cancer in Europe will change way of treatment

The recent approval of Europe's first personalized treatment for lung cancer heralds the arrival of a new era for lung cancer treatment that will demand significant changes to the way cancer specialists and other hospital doctors work, a leading expert said today at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

4 May 2010

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.

3 May 2010

Cancer Treatment News and Research

Researchers develop new technology to manage prostate cancer treatment

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Genetic tests represent future of cancer care for women

New computer-based tool developed to benefit cancer patients

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

Cancer costs double in 20 years but are still in line with overall health spending, study finds

Personalized treatments for thyroid disorders to be presented at ATA meeting

Costs and quality of cancer care in the U.S.

Curis reports net income of $4.8M for first-quarter 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

FDA approves Provenge for treating men with advanced prostate cancer

Decisive impact of informatics on nanomedicine

Canadian Cancer Society awards London scientists new funds for innovative research

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Theragenics reports highest quarterly consolidated revenue of $20.3 million

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Approval of personalized therapy for lung cancer in Europe will change way of treatment

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

Cancer Research eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News